- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04176068
Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity and Volume Restoration
February 1, 2024 updated by: Natasha Mesinkovska, University of California, Irvine
Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity
Non-invasive treatment options such as focused ultrasound has been used with success for the treatment of skin laxity in various parts of the body including the face, neck, décolletage, arms, buttocks, thighs, and legs.
With the increasing demand for greater results, researchers have started combining modalities together such as focused ultrasound and intradermal filler, with promising effects for skin laxity and volume restoration.
This study aims to elucidate the efficacy and added benefits of a combination therapy using focused ultrasound (Ulthera) and calcium hydroxylapatite (Radiesse) for the treatment of skin laxity and volume restoration of the lower thighs, specifically the lower anterior third of the thigh.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
20
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Irvine, California, United States, 92697
- University of California, Irvine Dermatology Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Exhibit skin aging and laxity that will benefit from treatment as determined by the investigator/physician.
- Subjects between the ages of 18-85 years old, at the time of consent.
- Subjects may be male or female.
- Subjects can be of any Fitzpatrick Skin type (I-VI).
- Subjects must be able and willing to give written informed consent and to comply with the requirements of this protocol. The consent form has been standardized in English. For those patients who do not read and understand English, a consent form will be standardized and provided in a language that they read and understand.
Exclusion Criteria:
- Children and adolescents (less than 18 years old).
- Subjects who are not willing or able to provide written consent.
- Individuals with any significant medical history including skin disorders and eating disorders as determined by the investigator/physician.
- Subjects on any substances affecting blood coagulation (including but not limited to aspirin and other non-steroid anti-inflammatory drugs, warfarin, vitamin E, fish oil, heparin, low-molecular weight heparin, novel anti-coagulants).
- Subjects with known blood coagulopathies.
- Subjects with a compromise of local blood supply (including but not limited to recent surgery, severe scarring, autoimmune diseases involving the lower thigh such as lupus, morphea, sarcoid or mixed connective tissue disease).
- Subjects who have received any treatment for skin laxity or liposuction in the last 12 weeks.
- Subjects who have experienced an increase or decrease in body weight of more than 10% in the past 24 weeks.
- Subjects who have a known hypersensitivity reaction to calcium hydroxylapatite or the components of the filler product.
- Subjects with open wounds in the area of ultrasound treatment.
- Subjects with pacemakers and/or electronic device implants in the area of ultrasound treatment.
- Female patients who are planning a pregnancy, currently pregnant or nursing.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Combined microfocused ultrasound and calcium hydroxylapatite
One-time intense microfocused ultrasound with calcium hydroxylapatite injection to one anterior lower thigh with option for additional filler injection at 6 weeks, 12 weeks, and 24 weeks.
Optional combined treatment of the opposite lower anterior thigh at week 24 with no further follow up.
|
Patients will receive IFUS to a randomly chosen side.
Immediately after IFUS treatment, patients will receive the first CaHA injection.
Injections will be given in the lower, anterior third of the thigh, above the knee.
Only dermatology faculty will perform the filler injections.
The patients will be instructed to return to the office in 6 weeks, 12 weeks, and 24 weeks (+/- 5 business days) for their next appointment for follow-up and injection of CaHA if deemed necessary by the investigator.
At all visits (Visits 1-4) patients will have photographs and unblinded physician/patient questionnaires will be completed.
At Visit 4 (24 weeks +/- 5 business days), patients will be given the option to receive treatment for skin laxity to the previously untreated side.
If the patient chooses to receive treatment, patients will receive their second IFUS and CaHA combination treatment at this time.
They will not receive further treatment after this visit.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of combined therapy at 12 weeks
Time Frame: 12 weeks
|
To determine the efficacy of intense focused ultrasound (IFUS) + calcium hydroxylapatite (CaHA) filler for the correction of skin laxity of the lower thigh as assessed by a blinded and an unblinded physician Global Aesthetic Improvement Scale (scale 1-7 with 1 being much improved and 7 being much worse) at 12 weeks.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of combined therapy at 24 weeks
Time Frame: 24 weeks
|
To determine the efficacy of IFUS and CaHA filler for the correction of skin laxity of the lower thigh as assessed by a blinded and an unblinded physician Global Aesthetic Improvement Scale (scale 1-7 with 1 being much improved and 7 being much worse) at 24 weeks.
|
24 weeks
|
Efficacy with Merz Aesthetic scale at 12 and 24 weeks
Time Frame: 24 weeks
|
To determine the efficacy of IFUS and CaHA filler for the correction of skin laxity of the lower thigh as assessed by a blinded and an unblinded physician Merz Aesthetic Scale (Grade 0-4 with 0 being no skin laxity and 4 being very severe skin laxity) at 12 and 24 weeks.
|
24 weeks
|
Patient satisfaction at 24 weeks
Time Frame: 24 weeks
|
To determine patient satisfaction 24 weeks post-treatment of IFUS + CaHA for the treatment of skin laxity of the lower thigh as assessed on a scale of 0-10 (with 0 being not satisfied and 10 being very satisfied).
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Natasha Mesinkovska, MD, PhD, University of California, Irvine
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 19, 2019
Primary Completion (Actual)
December 1, 2021
Study Completion (Actual)
December 1, 2021
Study Registration Dates
First Submitted
November 20, 2019
First Submitted That Met QC Criteria
November 21, 2019
First Posted (Actual)
November 25, 2019
Study Record Updates
Last Update Posted (Estimated)
February 2, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20184856
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Laxity
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Rocky Mountain Biosystems, Inc.CompletedLaxity of SkinUnited States
-
Merz North America, Inc.Ulthera, IncCompletedMild to Moderate Skin Laxity Under the Chin | Mild to Moderate Skin Laxity on NeckUnited States
-
Apsara Medical CorporationCompleted
-
Ulthera, IncCompletedSkin Laxity of the décolletéUnited States
-
Ulthera, IncUniversity of Texas Southwestern Medical CenterCompletedMild to Moderate Skin Laxity on Cheek | Mild to Moderate Skin Laxity on Upper Neck | Mild to Moderate Subcutaneous Fat on Cheek | Mild to Moderate Subcutaneous Fat on Upper Neck
-
Derming SRLCompletedFace Skin LaxityItaly
-
Nashville Centre for Laser and Facial SurgeryBausch HealthUnknownFacial Skin Laxity
-
Ulthera, IncCompletedFacial Skin LaxityUnited States
-
Endo PharmaceuticalsCompletedLaxity; Skin | Cellulite | Edematous Fibrosclerotic PanniculopathyUnited States
Clinical Trials on calcium hydroxylapatite (Radiesse) and IFUS (Ulthera)
-
DeNova ResearchMerz Aesthetics Inc.Completed
-
Northwestern UniversityWithdrawn
-
Cutis Medical Laser Clinics Pte LtdNot yet recruiting
-
The New York Eye & Ear InfirmaryThomas Jefferson UniversityCompletedWrinkles | RhytidsUnited States
-
University Hospital OstravaCompletedGlottic InsufficiencyCzechia
-
Goldman, Butterwick, Fitzpatrick and GroffMerz North America, Inc.Completed
-
Merz North America, Inc.CompletedCorrection of Moderate to Severe Nasolabial Folds (NLFs)China
-
Merz North America, Inc.CompletedCorrection of the Moderate to Severe Nasolabial FoldsChina
-
Erevna Innovations Inc.Completed
-
Ulthera, IncCompleted